Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Novo Nordisk presented its latest earnings with a detailed overview covering various aspects from financial metrics to research and development updates, contingent on forward-looking projections that may change.</li><li>The management emphasized strong commercial performance, especially in the diabetes and obesity segments, despite challenges in the rare disease category.</li><li>Financially, Novo Nordisk reported a robust 25% sales growth, marking an industry-leading progression.</li></ul>

Novo Nordisk presented its latest earnings with a detailed overview covering various aspects from financial metrics to research and development updates, contingent on forward-looking projections that may change.The management emphasized strong commercial performance, especially in the diabetes and obesity segments, despite challenges in the rare disease category.Financially, Novo Nordisk reported a robust 25% sales growth, marking an industry-leading progression.

Novo Nordisk: Will Their Expansion into the Obesity Market Pay Off? - Major Drivers

<ul><li>Based on the Q&A section from the latest earnings call transcript of Novo Nordisk, the investment thesis suggests a balanced appeal in various domains.</li><li>On the positive side, the company continues to sustain growing sales, operating profit, and strong pipeline development across multiple disease areas in the first quarter.</li><li>Novo Nordisk had a 24% sales growth, 30% operating profit growth, and a 24% sales growth.</li></ul>

Based on the Q&A section from the latest earnings call transcript of Novo Nordisk, the investment thesis suggests a balanced appeal in various domains.On the positive side, the company continues to sustain growing sales, operating profit, and strong pipeline development across multiple disease areas in the first quarter.Novo Nordisk had a 24% sales growth, 30% operating profit growth, and a 24% sales growth.

Novo Nordisk A/S: These Are The 6 Pivotal Factors Driving Its Performance In 2024 & Beyond! - Major Drivers

Covering IPOs, Healthcare and Technology Stocks

Andrei Zakharov

Equity Capital Markets

<ul>
<li>PegBio, a VC-backed biotech company, plans to tap capital markets in Hong Kong. CICC is leading the offering, and an IPO date has yet to be announced.</li>
<li>The company's pipeline features promising drug candidates designed for the treatment of type 2 diabetes mellitus (T2DM), obesity, NASH, OIC and congenital hyperinsulinemia. </li>
<li>PegBio employs a proprietary technology platform, called HECTOR, and has six drug candidates in the pipeline portfolio. PB-119 is their core product with the purpose to treat T2DM and obesity.</li>
</ul>


PegBio, a VC-backed biotech company, plans to tap capital markets in Hong Kong. CICC is leading the offering, and an IPO date has yet to be announced.
The company's pipeline features promising drug candidates designed for the treatment of type 2 diabetes mellitus (T2DM), obesity, NASH, OIC and congenital hyperinsulinemia. 
PegBio employs a proprietary technology platform, called HECTOR, and has six drug candidates in the pipeline portfolio. PB-119 is their core product with the purpose to treat T2DM and obesity.


PegBio IPO Preview: A Founder-Led Biopharma Player Fighting T2DM and Obesity in China

<ul><li>Novo Nordisk's latest earnings call showcased positive growth trends and strategic advancements for 2023.</li><li>The company was able to increase its patient base by 5 million, bringing the total to 42 million, without increasing CO2 emissions.</li><li>This reinforces Novo Nordisk's dedication to sustainability.</li></ul>

Novo Nordisk's latest earnings call showcased positive growth trends and strategic advancements for 2023.The company was able to increase its patient base by 5 million, bringing the total to 42 million, without increasing CO2 emissions.This reinforces Novo Nordisk's dedication to sustainability.

Novo Nordisk: Continuing Efforts and Opportunities in Obesity and Diabetes Treatment! - Major Drivers

<ul><li>Novo Nordisk A/S delivered a strong result and managed an all-around beat in the last quarter, boasting over 30% organic growth in both the top and bottom lines.</li><li>The quarter witnessed an impressive milestone, with the company reaching 40 million people affected by diabetes.</li><li>Financially, the company achieved a remarkable 33% sales growth and a 37% increase in operating profit at constant exchange rates.</li></ul>

Novo Nordisk A/S delivered a strong result and managed an all-around beat in the last quarter, boasting over 30% organic growth in both the top and bottom lines.The quarter witnessed an impressive milestone, with the company reaching 40 million people affected by diabetes.Financially, the company achieved a remarkable 33% sales growth and a 37% increase in operating profit at constant exchange rates.

Novo Nordisk A/S: Strategic Acquisition Of Embark Laboratories Fueling Their Growth in Obesity and Cardiometabolic Diseases! - Major Drivers

Denmark

Novo Nordisk A/S develops, produces, and markets pharmaceutical products. The Company focuses on diabetes care and offers insulin delivery systems and other diabetes products. Novo Nordisk also works in areas such as haemostatis management, growth disorders, and hormone replacement therapy. The Company offers educational and training materials. Novo Nordisk markets worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Novo Nordisk (NVO US)

Novo Nordisk: Will Their Expansion into the Obesity Market Pay Off? - Major Drivers

Novo Nordisk presented its latest earnings with a detailed overview covering various aspects from financial metrics to research and development...

Baptista Research

Novo Nordisk A/S: These Are The 6 Pivotal Factors Driving Its Performance In 2024 & Beyond! - Major Drivers

Based on the Q&A section from the latest earnings call transcript of Novo Nordisk, the investment thesis suggests a balanced appeal in various...

Baptista Research

PegBio IPO Preview: A Founder-Led Biopharma Player Fighting T2DM and Obesity in China

PegBio, a promising founder-led biotech company, is seeking to tap capital markets in Hong Kong. Their core product for the treatment of T2DM is at...

Andrei Zakharov

Novo Nordisk: Continuing Efforts and Opportunities in Obesity and Diabetes Treatment! - Major Drivers

Novo Nordisk's latest earnings call showcased positive growth trends and strategic advancements for 2023. The company was able to increase its...

Baptista Research

Novo Nordisk A/S: Strategic Acquisition Of Embark Laboratories Fueling Their Growth in Obesity and Cardiometabolic Diseases! - Major Drivers

Novo Nordisk A/S delivered a strong result and managed an all-around beat in the last quarter, boasting over 30% organic growth in both the top...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)